Small nucleic acids and the path to the clinic for anti-CRISPR.
Small nucleic acids and the path to the clinic for anti-CRISPR.
复制标题
DOI:
10.1016/j.bcp.2021.114492
复制
发表时间:
2021-07
影响因子:
5.8
通讯作者:
Gagnon KT
中科院分区:
文献类型:
--
作者:
Barkau CL;O'Reilly D;Eddington SB;Damha MJ;Gagnon KT
CRISPR-based therapeutics have entered clinical trials but no methods to inhibit Cas enzymes have been demonstrated in a clinical setting. The ability to inhibit CRISPR-based gene editing or gene targeting drugs should be considered a critical step in establishing safety standards for many CRISPR-Cas therapeutics. Inhibitors can act as a failsafe or as an adjuvant to reduce off-target effects in patients. In this review we discuss the need for clinical inhibition of CRISPR-Cas systems and three existing inhibitor technologies: anti-CRISPR (Acr) proteins, small molecule Cas inhibitors, and small nucleic acid-based CRISPR inhibitors, CRISPR SNuBs. Due to their unique properties and the recent successes of other nucleic acid-based therapeutics, CRISPR SNuBs appear poised for clinical application in the near-term.
登录
查看更多内容
DOI:
10.1126/science.aaf5573
发表时间:
2016-08-05
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Abudayyeh OO;Gootenberg JS;Konermann S;Joung J;Slaymaker IM;Cox DB;Shmakov S;Makarova KS;Semenova E;Minakhin L;Severinov K;Regev A;Lander ES;Koonin EV;Zhang F
通讯作者:
Zhang F
影响因子:
5.6
作者:
Dias, N;Dheur, S;Saison-Behmoaras, TE
通讯作者:
Saison-Behmoaras, TE
影响因子:
64.8
作者:
Bondy-Denomy J;Garcia B;Strum S;Du M;Rollins MF;Hidalgo-Reyes Y;Wiedenheft B;Maxwell KL;Davidson AR
通讯作者:
Davidson AR
影响因子:
14.9
作者:
Cuellar TL;Barnes D;Nelson C;Tanguay J;Yu SF;Wen X;Scales SJ;Gesch J;Davis D;van Brabant Smith A;Leake D;Vandlen R;Siebel CW
通讯作者:
Siebel CW
影响因子:
14.8
作者:
Davis, Kevin M.;Pattanayak, Vikram;Thompson, David B.;Zuris, John A.;Liu, David R.
通讯作者:
Liu, David R.